Moustafa Moustafa, MD
Nephrology · Orangeburg, SCNPI 1356431449
Payments from drug & device makers
Across 2,194 payments — averaging $1371.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$540K
- Akebia Therapeutics Inc$529K
- OPKO Pharmaceuticals, LLC$362K
- Genentech, Inc.$273K
- AstraZeneca$262K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$183K
- plus $860K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 883 | $540,110 |
| Akebia Therapeutics Inc | 447 | $529,098 |
| OPKO Pharmaceuticals, LLC | 65 | $362,180 |
| Genentech, Inc. | 26 | $273,337 |
| AstraZeneca(2 entities) | 81 | $262,254 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $183,079 |
| Bayer | 85 | $175,098 |
| GSK | 27 | $170,371 |
| Vertex | 10 | $164,976 |
| Pfizer | 22 | $141,099 |
| Merck | 3 | $88,085 |
| Astrazeneca UK Limited | 8 | $26,618 |
| Amgen(2 entities) | 55 | $23,058 |
| Novo Nordisk AS | 327 | $22,603 |
| AbbVie | 1 | $17,394 |
| Novartis | 4 | $10,753 |
| Ardelyx, Inc. | 15 | $8,298 |
| Vifor Pharma, Inc. | 33 | $5,434 |
| Calliditas Therapeutics US Inc. | 18 | $2,044 |
| Biogen | 1 | $1,753 |
| Aurinia Pharma U.S., Inc. | 18 | $565 |
| Otsuka America Pharmaceutical, Inc. | 17 | $451 |
| Mallinckrodt Enterprises LLC | 3 | $262 |
| Mallinckrodt Hospital Products Inc. | 3 | $162 |
| Renalytix AI, Inc. | 6 | $116 |
| Boehringer Ingelheim | 5 | $113 |
| Travere Therapeutics, Inc. | 7 | $103 |
| Corcept Therapeutics | 5 | $96 |
| Nxstage Medical, Inc. | 2 | $80 |
| Scpharmaceuticals Inc. | 3 | $61 |
| Ultragenyx Pharmaceutical Inc. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 3 | $40 |
| Sanofi | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $20 |
How this compares
$3,009,859 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Orangeburg
- Jalal Eddin HakmeiOrangeburg$7K
- Barry GorlitskyGreenville$3.1M
- Amy SpragueGeorgetown$1.5M
- Pusadee SuchindaSumter$1.3M
- Jessica ColemanBeaufort$930K
- Asha BaileyColumbia$724K
- Thomas PowellColumbia$704K
- Roberto PisoniCharleston$512K
- Harold SzerlipCharleston$443K
- Howard LiflandColumbia$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.